Vaccine最新文献

{"title":"The genetic, biophysical and immunological studies of a self-adjuvanted protein nanoparticle","authors":"Jyun-Hong Lyu ,&nbsp;Gunn-Guang Liou ,&nbsp;May Wang ,&nbsp;Ming-Chung Kan","doi":"10.1016/j.vaccine.2025.127087","DOIUrl":"10.1016/j.vaccine.2025.127087","url":null,"abstract":"<div><div>Adjuvant is required for boosting the immune responses for subunit vaccine. An emerging category of vaccine adjuvant is the self-assembling peptide that forms fibril and stimulates both humoral and cellular immunities. Based on our previous finding that a stabilized self-assembled protein nanoparticle (PNP), also called Vaccine Delivery system X (VADEX), assembled from a fusion protein composed of an amphipathic helical peptide and a superfolder green fluorescent protein can stimulate long lasting immune responses to an inserted peptide. In this report, we further introduced split-GFP technology into VADEX and evaluated the role of the amphipathic helical peptide integrity, thermal stability of PNP and the effect of self-adjuvant in antibody affinity maturation of this new platform, VADEX-pro. Our result shows the significance of amphipathic helical peptide sequence integrity in PNP assembly and the thermal stability. The immunological results provide the first evidence that the VADEX-pro PNP possess a self-adjuvant activity that is superior to a clinical stage adjuvant when evaluating the antibody binding affinity. Application of VADEX-pro based protein nanoparticle in vaccine and therapeutic antibody development will likely improve the quality of humoral immune responses.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"56 ","pages":"Article 127087"},"PeriodicalIF":4.5,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143855576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The novel antigen, lipopolysaccharide export protein LptH, protects mice against Pseudomonas aeruginosa acute pneumonia in monovalent and multivalent vaccines","authors":"Irene Jurado-Martín,&nbsp;Julen Tomás-Cortázar,&nbsp;Nouran Rezk,&nbsp;Yueran Hou,&nbsp;Maite Saínz-Mejías,&nbsp;Rhys Bruce,&nbsp;Maryna Startseva,&nbsp;Chaoying Ma,&nbsp;Siobhán McClean","doi":"10.1016/j.vaccine.2025.127145","DOIUrl":"10.1016/j.vaccine.2025.127145","url":null,"abstract":"<div><div><em>Pseudomonas aeruginosa</em> is a Gram-negative opportunistic pathogen that is a leading cause of morbidity and mortality worldwide in susceptible patients, particularly in those with respiratory disorders. The rising prevalence of multidrug-resistant strains and the failure of previous <em>P. aeruginosa</em> vaccine candidates in clinical trials highlight the urgent need to investigate novel vaccine antigens. In this study, we evaluated the protective potential of two antigen candidates, LptH and OprM, previously identified based on their involvement in host-cell attachment in a murine acute pneumonia model. Recombinant <em>Escherichia coli</em> BL21 clones overexpressing these proteins showed 8.8- and 3.5-fold increased attachment to 16HBE14o⁻ cells in vitro<em>,</em> confirming their role in host-cell attachment. Immunisation with rLptH significantly reduced bacterial burden in the lungs by 1.12 log₁₀ CFU and improved animal welfare scores compared to adjuvant-only controls. Serological and immunophenotyping analyses revealed that the monovalent rLptH vaccine stimulated antigen-specific IgG1 and IgG2c isotype production, and enhanced IFN-γ and IL-17 recall responses in the spleen. Moreover, a trivalent vaccine comprising rLptH and two other <em>P. aeruginosa</em> antigens, rFtsZ, and rOpmH, achieved a 2.33 log₁₀ CFU reduction in lung bacterial burden, and 1.85 log₁₀ CFU reduction in dissemination. These encouraging findings support the potential of LptH as a promising antigen for the development of a protective multivalent vaccine against <em>P. aeruginosa</em> infections.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"56 ","pages":"Article 127145"},"PeriodicalIF":4.5,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143851957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Nasopharyngeal carriage of Streptococcus pneumoniae among children and their household members in southern Mozambique five years after PCV10 introduction” Vaccine, Volume 47, 15 February 2025, 126,691","authors":"Rebecca Kahn ,&nbsp;Benild Moiane ,&nbsp;Fernanda C. Lessa ,&nbsp;Sergio Massora ,&nbsp;Viviana Mabombo ,&nbsp;Alberto Chauque ,&nbsp;Nelson Tembe ,&nbsp;Helio Mucavele ,&nbsp;Cynthia G. Whitney ,&nbsp;Charfudin Sacoor ,&nbsp;Graca Matsinhe ,&nbsp;Fabiana C. Pimenta ,&nbsp;Maria da Gloria Carvalho ,&nbsp;Betuel Sigauque ,&nbsp;Jennifer Verani","doi":"10.1016/j.vaccine.2025.127124","DOIUrl":"10.1016/j.vaccine.2025.127124","url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"56 ","pages":"Article 127124"},"PeriodicalIF":4.5,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143855325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Herpes zoster vaccination coverage and factors associated among adults aged 40 and older in China: A population-based survey","authors":"Yiqi Xia ,&nbsp;Wenhui Zhu ,&nbsp;Zhenyu Shi ,&nbsp;Yang Shen ,&nbsp;Chengsen Cui ,&nbsp;Jinxu Ai ,&nbsp;Yemin Yuan ,&nbsp;Xin Ye ,&nbsp;Dawei Zhu ,&nbsp;Ping He","doi":"10.1016/j.vaccine.2025.127122","DOIUrl":"10.1016/j.vaccine.2025.127122","url":null,"abstract":"<div><h3>Objectives</h3><div>Herpes zoster (HZ) is a significant public health issue in China, especially with an aging population and rising incidence. While vaccination effectively prevents HZ and its complications, national data on HZ vaccine (HZV) coverage and associated factors in China are limited.</div></div><div><h3>Methods</h3><div>We conducted a nationwide survey across 25 provinces in mainland China, including 14,315 participants aged over 40 years, to estimate HZV uptake and associated factors among adults aged 40 years and older. Multivariate logistic regression was used to assess characteristics linked to vaccination, and we analysed vaccine types and dose completion rates.</div></div><div><h3>Results</h3><div>The HZV uptake rate was 0.79 %. Vaccination was more likely among individuals with middle school education and higher household income. Most vaccinated individuals received the zoster vaccine live (ZVL) rather than the recombinant zoster vaccine (RZV), and nearly half completed two doses.</div></div><div><h3>Conclusions</h3><div>HZV coverage in China is low, underscoring the need for targeted public health strategies to improve vaccine accessibility and awareness, particularly among at-risk groups, to reduce HZ-related burdens.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"56 ","pages":"Article 127122"},"PeriodicalIF":4.5,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143848278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regional cooperation on pandemic preparedness and vaccine equity from an economic, regulatory and legal perspective","authors":"Mei Xuan Jessalyn Chan ,&nbsp;Olivier J. Wouters ,&nbsp;Hui Yun Chan ,&nbsp;Petro Terblanche ,&nbsp;Nakorn Premsri ,&nbsp;Jerome H. Kim ,&nbsp;John C.W. Lim ,&nbsp;Wei Chuen Tan-Koi ,&nbsp;Mark Jit","doi":"10.1016/j.vaccine.2025.127107","DOIUrl":"10.1016/j.vaccine.2025.127107","url":null,"abstract":"<div><div>The COVID-19 pandemic has underscored the need for a global agreement to strengthen international health regulations. However, progress towards such an agreement has been deferred to a future World Health Assembly and is likely to be further hampered by an increasingly uncertain global geopolitical context, a delay which we cannot afford. In the interim, urgent immediate action to intensify regional cooperation on pandemic preparedness and vaccine equity is needed. The three key aspects of intensified regional cooperation are: financial and economic sustainability, regulatory systems strengthening and legal frameworks that facilitate cooperation. While there is still momentum, the global community must act swiftly and cohesively, intensifying regional cooperation to strengthen governance on pandemic prevention, preparedness and response.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"53 ","pages":"Article 127107"},"PeriodicalIF":4.5,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143850352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incorporating vaccines into vaccination schedules around the world: A scoping review","authors":"Ana Catarina de Melo Araújo ,&nbsp;Thaís Moreira Oliveira ,&nbsp;Janaina Fonseca Almeida Souza ,&nbsp;Thayssa Neiva da Fonseca Victer ,&nbsp;Petra Santos Castro Rangel ,&nbsp;Camila Kümmel Duarte ,&nbsp;Thales Philipe Rodrigues da Silva ,&nbsp;Fernanda Penido Matozinhos ,&nbsp;Eder Gatti Fernandes","doi":"10.1016/j.vaccine.2025.127132","DOIUrl":"10.1016/j.vaccine.2025.127132","url":null,"abstract":"<div><h3>Introduction</h3><div>Over the past 50 years, immunization initiatives and programs promoted by member countries of the World Health Organization have prevented approximately 154 million deaths, 146 million of which would have occurred among children under 5 years of age. The development of vaccines and implementing global immunization strategies against vaccine-preventable diseases have been instrumental in enhancing global health security.</div></div><div><h3>Objective</h3><div>To analyze the process of integrating new vaccines into vaccination schedules worldwide.</div></div><div><h3>Methodology</h3><div>This study is a scoping review, conducted in accordance with the 2024 Joanna Briggs Institute Manual for Evidence Synthesis and reported following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses - Extension for Scoping Reviews</div></div><div><h3>Results</h3><div>The search strategy yielded 2432 citations, with 688 removed due to duplication. Consequently, 1744 titles and abstracts were assessed, resulting in 75 studies being included in the review. The majority of these studies found that the assessment process for incorporating new vaccines primarily aims at reducing costs and/or promoting collective and individual social and economic benefits, with most focusing on the vaccination schedule for children up to 12 years of age. To evaluate the social and economic aspects, the predominant strategies were cost-effectiveness and cost-benefit analyses of new vaccine incorporation. The most frequently employed tools included the incremental cost-effectiveness ratio, years of life lost adjusted for disability, years of life adjusted for quality, and the Markov model.</div></div><div><h3>Final Considerations</h3><div>The process of vaccine incorporation has been shown to extend beyond immediate health impacts, encompassing social improvements and cost optimization capable of producing long-term effects.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 127132"},"PeriodicalIF":4.5,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143844231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nationwide population-based surveillance of invasive pneumococcal disease in children in Japan (2014–2022): Impact of 13-valent pneumococcal conjugate vaccine and COVID-19 pandemic","authors":"Noriko Takeuchi ,&nbsp;Bin Chang ,&nbsp;Naruhiko Ishiwada ,&nbsp;Yoshiaki Cho ,&nbsp;Junichiro Nishi ,&nbsp;Kenji Okada ,&nbsp;Mikiya Fujieda ,&nbsp;Megumi Oda ,&nbsp;Akihiko Saitoh ,&nbsp;Mitsuaki Hosoya ,&nbsp;Nobuhisa Ishiguro ,&nbsp;Kohei Takahashi ,&nbsp;Yoshihito Ozawa ,&nbsp;Shigeru Suga","doi":"10.1016/j.vaccine.2025.127138","DOIUrl":"10.1016/j.vaccine.2025.127138","url":null,"abstract":"<div><h3>Background</h3><div>Nationwide surveillance was conducted in Japan to clarify the status of pediatric invasive pneumococcal diseases (IPD) after introducing a 13-valent pneumococcal conjugate vaccine (PCV13).</div></div><div><h3>Methods</h3><div>Detailed clinical and epidemiologic information of IPD cases in children aged &lt;15 years was collected from 10 of 47 prefectures in Japan from January 2014 to December 2022. <em>Streptococcus pneumoniae</em> strains isolated from sterile body sites were analyzed including capsular serotypes, multi-locus sequence typing (MLST), and antimicrobial susceptibility testing. The serotype-specific IPD incidence was calculated by imputing the serotypes for missing isolates to serotypes assumed based on the distribution of known serotypes.</div></div><div><h3>Results</h3><div>During the study period, 1033 IPD cases were reported. The incidence rate of total IPD in patients aged &lt;5 years from 2014 to 2019 declined by 21.3 % compared with the rate from 2011 to 2013 before the introduction of PCV13. Compared with the incidence of total IPD from 2014 to 2019 and from 2020 to 2022, during the COVID-19 pandemic, the incidence of IPD among children aged &lt;5 years declined by 49.7 %. In total, 932 IPD cases were identified as capsular serotypes. Among children aged &lt;5 years, the most frequent serotype was 24F, followed by 15 A, 12F, 15C, 15B, and 10 A. Since 2014, after replacement with PCV13 in 2013, the rate of IPD by PCV13 minus PCV7 serotypes decreased, and non-PCV13 serotypes further increased. The serotype causing IPD in children aged &lt;5 years, with PCV15-unique serotypes and PCV20-unique serotype were 8.6 % and 22.5 %, respectively. In terms of antimicrobial susceptibility, strains resistant to penicillin and cefotaxime decreased, whereas the meropenem non-susceptible strains increased in the post-PCV13 era.</div></div><div><h3>Conclusion</h3><div>PCV13 introduction and the COVID-19 pandemic have had a significant impact on pediatric IPD in Japan. It is important to continuously monitor the epidemiological characteristics of pediatric IPD after the introduction of PCV20.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 127138"},"PeriodicalIF":4.5,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143848645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge-based mitigation of the environmental risk of Orthoflavivirus live-attenuated vaccines by targeting viral encoded determinants for the mosquito attenuated phenotype","authors":"Emily K. Mantlo,&nbsp;Yan-Jang S. Huang","doi":"10.1016/j.vaccine.2025.127114","DOIUrl":"10.1016/j.vaccine.2025.127114","url":null,"abstract":"<div><div>Many mosquito-borne orthoflaviviruses are important public health problems. Vaccination is critical for disease control because there is no licensed antiviral therapy for any orthoflavivirus. Live-attenuated vaccines (LAVs) that elicit protective immunity with one single immunization are the most effective tool for disease control, as shown by the success of implementing yellow fever (YF) 17D and Japanese encephalitis (JE) SA14–14-2 vaccines in routine immunization programs within endemic regions. Importantly, neither the YFV 17D strain nor the JEV SA14–14-2 LAV strain are mosquito-competent, meaning that neither vaccine strain can effectively infect and disseminate in mosquito tissues following engorgement of viremic blood. The mosquito-attenuated phenotype also ensures the safety of the licensed LAVs IMOJEV, Dengvaxia and QDENGA. In the 21st century, regulators expect the attenuated phenotype of candidate orthoflavivirus LAVs to also include a demonstration of reduced replication and dissemination in arthropod vectors under laboratory conditions in order to support environmental risk assessments of the impacts of these LAVs in nature. Achieving a safe level of attenuation of orthoflaviviruses in mosquitoes requires multigenic mutations to prevent reversion to the wild-type phenotype. This review discusses knowledge of orthoflaviviral encoded determinants for infection and dissemination in mosquito tissues which have potential utility for the rational design of candidate LAVs. Several attenuating mutations discovered to date are located within genomic regions that are conserved among orthoflaviviruses and can potentially support the establishment of a broadly effective attenuating strategy.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 127114"},"PeriodicalIF":4.5,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143844230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating concurrency and gaps between self-report and vaccine card data for COVID-19 vaccination","authors":"Marie C.D. Stoner ,&nbsp;Jenna Michaels ,&nbsp;Jacob B. Stocks ,&nbsp;Noah Mancuso ,&nbsp;Zachary Soberano ,&nbsp;Erica Browne ,&nbsp;C. Lily Bond ,&nbsp;Ibrahim Yigit ,&nbsp;Allysha C. Maragh-Bass ,&nbsp;Audrey E. Pettifor ,&nbsp;Kathryn E. Muessig ,&nbsp;Maria Leonora G. Comello ,&nbsp;Margo Adams Larsen ,&nbsp;Lisa B. Hightow-Weidman ,&nbsp;Henna Budhwani","doi":"10.1016/j.vaccine.2025.127136","DOIUrl":"10.1016/j.vaccine.2025.127136","url":null,"abstract":"<div><div>We compared self-reported vaccination to vaccine card data to assess concurrency in a sample of Black young adults in Georgia, Alabama, and North Carolina. We described vaccine card versus self-reported data over time and examined discrepancies in reporting between these two sources. Results indicated strong currency suggesting collection of self-reported data may be an acceptable proxy to requiring official vaccine documentation. However, since 58 % of participants did not upload a vaccine card, finding should be applied with caution. Minor differences were found and were generally due to boosters that were self-reported but were not on cards. The discrepancy in number of vaccines and boosters was likely because COVID-19 vaccination has become routine and vaccine cards are not being updated regularly. At this stage in the pandemic and for other vaccinations that become routine and are administered at pharmacies, self-report may be a reliable indication of the number of vaccinations received.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 127136"},"PeriodicalIF":4.5,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of recombinant Lactobacillus vector-based expressing IFITM3 protein anti-PRV infection in mice.","authors":"Fan Zheng ,&nbsp;Maokun Zhu ,&nbsp;Hengdong Ran ,&nbsp;Jiayi He ,&nbsp;Binghan Bai ,&nbsp;Simeng Feng ,&nbsp;Wei Dong ,&nbsp;Bin Li ,&nbsp;Lixin Wen ,&nbsp;Xiaomin Yuan","doi":"10.1016/j.vaccine.2025.127093","DOIUrl":"10.1016/j.vaccine.2025.127093","url":null,"abstract":"<div><div>Pseudorabies virus (PRV) causes high mortality encephalitis in newborn piglets, abortion and stillbirth in sows, resulting in huge economic losses to the swine industry. Interferon-induced transmembrane proteins (IFITMs) play a crucial role in the innate immune response triggered by viral infection. Lactic acid bacteria (LABs) are good candidates for the development of new oral vaccines and are attractive alternatives to attenuated pathogens. “Here we tested the capacity of a LAB vector expressing the IFITM3 protein (r-LAB-I3), delivered by oral gavage, to protect mice against PRV challenge. Furthermore, the r-LAB-I3 treated groups showed markedly diminished levels of viral DNA in brain, lung, spleen and liver tissues, which resulted in protection against brain and lung damage. Moreover, the inhibitory effect of IFITM3 on PRV circumvents the upregulation of inflammatory cytokines. As r-LAB-I3 oral gavage platforms can restrict in various organs and tissues of PRV in mice, recombinant LAB may generate additional innovative and efficient live vector anti-PRV candidates.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 127093"},"PeriodicalIF":4.5,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}